Correction: Preventing tumor escape by targeting a post-proteasomal trimming independent epitope [The Journal of Experimental Medicine, 213, 11, (2016) (2333-2348)] DOI: 10.1084/jem.20160636;Preventing tumor escape by targeting a post-proteasomal trimming independent epitope

Journal of Experimental Medicine

Volumn 213, Issue 11, 2016, Pages 2333-2348

  Textor, Ana ^a   Schmidt, Karin ^a,b   Kloetzel, Peter M ^b,c   Weißbrich, Bianca ^d   Perez, Cynthia ^a   Charo, Jehad ^a   Anders, Kathleen ^a   Sidney, John ^e   Sette, Alessandro ^e   Schumacher, Ton N M ^f   Keller, Christin ^b   Busch, Dirk H ^d   Seifert, Ulrike ^b,g,h   Blankenstein, Thomas ^a,b,c  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c BERLIN INSTITUTE OF HEALTH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^f NETHERLANDS CANCER INSTITUTE   (Netherlands)

^g OTTO VON GUERICKE UNIVERSITY   (Germany)

^h UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; PROTEASOME; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR I; T LYMPHOCYTE RECEPTOR IV; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ANTIGEN; CYTOSOL AMINOPEPTIDASE; HLA ANTIGEN CLASS 1; LYMPHOCYTE ANTIGEN RECEPTOR; PEPTIDE; PUROMYCIN-INSENSITIVE LEUCYL-SPECIFIC AMINOPEPTIDASE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL SURFACE; CELL THERAPY; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; IMMUNOSTIMULATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; METASTATIC MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T CELL CULTURE; TUMOR ESCAPE; TUMOR IMMUNOLOGY; TUMOR RECURRENCE; TUMOR REJECTION; TUMOR VOLUME; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; ANTIBODY AFFINITY; C57BL MOUSE; CHEMISTRY; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; ANTIGENS; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERFERON-GAMMA; LEUCYL AMINOPEPTIDASE; MICE, INBRED C57BL; NEOPLASMS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 85013765346     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.2016063601122017c     Document Type: Erratum

References (62)

1. Abril, E., L.M. Real, A. Serrano, P. Jimenez, A. García, J. Canton, I. Trigo, F. Garrido, and F. Ruiz-Cabello. 1998. Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol. Immunother. 47:113-120. http://dx.doi.org/10.1007/s002620050511
2. Anders, K., and T. Blankenstein. 2013. Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes. Clin. Cancer Res. 19:320-326. http://dx.doi.org/10.1158/1078-0432.CCR-12-3017
3. Anders, K., C. Buschow, A. Herrmann, A. Milojkovic, C. Loddenkemper, T. Kammertoens, P. Daniel, H. Yu, J. Charo, and T. Blankenstein. 2011. Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer. Cancer Cell. 20:755-767. http://dx.doi.org/10.1016/j.ccr.2011.10.019
4. Anders, K., C. Buschow, J. Charo, and T. Blankenstein. 2012. Depot formation of doxycycline impairs Tet-regulated gene expression in vivo. Transgenic Res. 21:1099-1107. http://dx.doi.org/10.1007/s11248-011-9580-0
5. Androlewicz, M.J., K.S. Anderson, and P. Cresswell. 1993. Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. Proc. Natl. Acad. Sci. USA. 90:9130-9134. http://dx.doi.org/10.1073/pnas.90.19.9130
6. Bendle, G.M., C. Linnemann, L. Bies, J.-Y. Song, and T.N.M. Schumacher. 2013. Blockade of TGF-β signaling greatly enhances the efficacy of TCR gene therapy of cancer. J. Immunol. 191:3232-3239. http://dx.doi.org/10.4049/jimmunol.1301270
7. Briesemeister, D., D. Sommermeyer, C. Loddenkemper, R. Loew, W. Uckert, T. Blankenstein, and T. Kammertoens. 2011. Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis. Int. J. Cancer. 128:371-378. http://dx.doi.org/10.1002/ijc.25350
8. Bukur, J., S. Jasinski, and B. Seliger. 2012. The role of classical and non-classical HLA class I antigens in human tumors. Semin. Cancer Biol. 22:350-358. http://dx.doi.org/10.1016/j.semcancer.2012.03.003
9. Buschow, C., J. Charo, K. Anders, C. Loddenkemper, A. Jukica, W. Alsamah, C. Perez, G. Willimsky, and T. Blankenstein. 2010. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance. J. Immunol. 184:2930-2938. http://dx.doi.org/10.4049/jimmunol.0900893
10. Chang, C.-C., and S. Ferrone. 2007. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol. Immunother. 56:227-236. http://dx.doi.org/10.1007/s00262-006-0183-1
11. Charo, J., C. Perez, C. Buschow, A. Jukica, M. Czeh, and T. Blankenstein. 2011. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur. J. Immunol. 41:3187-3197. http://dx.doi.org/10.1002/eji.201141452
12. Cheng, Y., and W.H. Prusoff. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108. http://dx.doi.org/10.1016/0006-2952(73)90196-2
13. Cormier, J.N., M.C. Panelli, J.A. Hackett, M.P. Bettinotti, A. Mixon, J. Wunderlich, L.L. Parker, N.P. Restifo, S. Ferrone, and F.M. Marincola. 1999. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int. J. Cancer. 80:781-790. http://dx.doi.org/10.1002/(SICI)1097.-0215(19990301)80 :5<781::AID-IJC24>3.0.CO;2-A
14. Dighe, A.S., E. Richards, L.J. Old, and R.D. Schreiber. 1994. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1:447-456. http://dx.doi.org/10.1016/1074-7613(94)90087-6
15. Draenert, R., S. Le Gall, K.J. Pfafferott, A.J. Leslie, P. Chetty, C. Brander, E.C. Holmes, S.-C. Chang, M.E. Feeney, M.M. Addo, et al. 2004. Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection. J. Exp. Med. 199:905-915. http://dx.doi.org/10.1084/jem.20031982
16. Dunn, G.P., K.C.F. Sheehan, L.J. Old, and R.D. Schreiber. 2005. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 65:3447-3453. http://dx.doi.org/10.1158/0008.-5472.CAN-04-4316
17. Engels, B., V.H. Engelhard, J. Sidney, A. Sette, D.C. Binder, R.B. Liu, D.M. Kranz, S.C. Meredith, D.A. Rowley, and H. Schreiber. 2013. Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 23:516-526. http://dx.doi.org/10.1016/j.ccr.2013.03.018
18. Feenstra, M., M. Veltkamp, J. van Kuik, S. Wiertsema, P. Slootweg, J. van den Tweel, R. de Weger, and M. Tilanus. 1999. HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas. Tissue Antigens. 54:235-245. http://dx.doi.org/10.1034/j.1399-0039.1999.540304.x
19. Gallimore, A., T. Dumrese, H. Hengartner, R.M. Zinkernagel, and H.-G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1647-1657. http://dx.doi.org/10.1084/jem.187.10.1647-b
20. Garbi, N., B. Arnold, S. Gordon, G.J. Hämmerling, and R. Ganss. 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172:5861-5869. http://dx.doi.org/10.4049/jimmunol.172.10.5861
21. Garrido, C., L. Paco, I. Romero, E. Berruguilla, J. Stefansky, A. Collado, I. Algarra, F. Garrido, and A.M. Garcia-Lora. 2012. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells. Carcinogenesis. 33:687-693. http://dx.doi.org/10.1093/carcin/bgr318
22. Gulukota, K., J. Sidney, A. Sette, and C. DeLisi. 1997. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. J. Mol. Biol. 267:1258-1267. http://dx.doi.org/10.1006/jmbi.1997.0937
23. Hammer, G.E., F. Gonzalez, M. Champsaur, D. Cado, and N. Shastri. 2006. The aminopeptidase ERA AP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat. Immunol. 7:103-112. http://dx.doi.org/10.1038/ni1286
24. Hammer, G.E., F. Gonzalez, E. James, H. Nolla, and N. Shastri. 2007. In the absence of aminopeptidase ERA AP, MHC class I molecules present many unstable and highly immunogenic peptides. Nat. Immunol. 8:101-108. http://dx.doi.org/10.1038/ni1409
25. James, E., I. Bailey, G. Sugiyarto, and T. Elliott. 2013. Induction of protective antitumor immunity through attenuation of ERA AP function. J. Immunol. 190:5839-5846. http://dx.doi.org/10.4049/jimmunol.1300220
26. Kaplan, D.H., V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, L.J. Old, and R.D. Schreiber. 1998. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA. 95:7556-7561. http://dx.doi.org/10.1073/pnas.95.13.7556
27. + T cell responses by targeting the aminopeptidase ERAP1. Nat. Immunol. 12:984-991. http://dx.doi.org/10.1038/ni.2097
28. Kloetzel, P.M., and F. Ossendorp. 2004. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 16:76-81. http://dx.doi.org/10.1016/j.coi.2003.11.004
29. Leal, J.F., J. Fominaya, A. Cascón, M.V. Guijarro, C. Blanco-Aparicio, M. Lleonart, M.E. Castro, S. Ramon Y Cajal, M. Robledo, D.H. Beach, and A. Carnero. 2008. Cellular senescence bypass screen identifies new putative tumor suppressor genes. Oncogene. 27:1961-1970. http://dx.doi.org/10.1038/sj.onc.1210846
30. Listopad, J.J., T. Kammertoens, K. Anders, B. Silkenstedt, G. Willimsky, K. Schmidt, A.A. Kuehl, C. Loddenkemper, and T. Blankenstein. 2013. Fas expression by tumor stroma is required for cancer eradication. Proc. Natl. Acad. Sci. USA. 110:2276-2281. http://dx.doi.org/10.1073/pnas.1218295110
31. + T cells in tumor-bearing mice. J. Immunol. 174:2563-2572. http://dx.doi.org/10.4049/jimmunol.174.5.2563
32. + T cells for the treatment of patients with metastatic melanoma. J. Clin. Oncol. 24:5060-5069. http://dx.doi.org/10.1200/JCO.2006.07.1100
33. Mehta, A.M., E.S. Jordanova, W.E. Corver, T. van Wezel, H.-W. Uh, G.G. Kenter, and G. Jan Fleuren. 2009. Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes Chromosomes Cancer. 48:410-418. http://dx.doi.org/10.1002/gcc.20648
34. Mishto, M., J. Liepe, K. Textoris-Taube, C. Keller, P. Henklein, M. Weberruß, B. Dahlmann, C. Enenkel, A. Voigt, U. Kuckelkorn, et al. 2014. Proteasome isoforms exhibit only quantitative differences in cleavage and epitope generation. Eur. J. Immunol. 44:3508-3521. http://dx.doi.org/10.1002./eji.201444902
35. Mumberg, D., P.A. Monach, S. Wanderling, M. Philip, A.Y. Toledano, R.D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA. 96:8633-8638. http://dx.doi.org/10.1073/pnas.96.15.8633
36. + T-lymphocyte responses to multiple epitopes from simian virus 40. (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40. T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J. Virol. 74:6922-6934. http://dx.doi.org/10.1128/JVI.74.15.6922-6934.2000
37. + T cells for adoptive transfer. Sci. Transl. Med. 5:192ra87. http://dx.doi.org/10.1126/scitranslmed.3005958
38. Otahal, P., B.B. Knowles, S.S. Tevethia, and T.D. Schell. 2007. Anti-CD40. conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigeninduced pancreatic tumors. J. Immunol. 179:6686-6695. http://dx.doi.org/10.4049/jimmunol.179.10.6686
39. Paschen, A., R.M. Méndez, P. Jimenez, A. Sucker, F. Ruiz-Cabello, M. Song, F. Garrido, and D. Schadendorf. 2003. Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events. Int. J. Cancer. 103:759-767. http://dx.doi.org/10.1002/ijc.10906
40. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by nonhematopoietic cells. Immunity. 12:677-686. http://dx.doi.org/10.1016/S1074-7613(00)80218-6
41. Respa, A., J. Bukur, S. Ferrone, G. Pawelec, Y. Zhao, E. Wang, F.M. Marincola, and B. Seliger. 2011. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin. Cancer Res. 17:2668-2678. http://dx.doi.org/10.1158/1078.-0432.CCR-10-2114
42. Restifo, N.P., F.M. Marincola, Y. Kawakami, J. Taubenberger, J.R. Yannelli, and S.A. Rosenberg. 1996. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl. Cancer Inst. 88:100-108. http://dx.doi.org/10.1093/jnci/88.2.100
43. Rock, K.L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A.L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 78:761-771. http://dx.doi.org/10.1016/S0092-8674(94)90462-6
44. Rosenberg, S.A., J.C. Yang, R.M. Sherry, U.S. Kammula, M.S. Hughes, G.Q. Phan, D.E. Citrin, N.P. Restifo, P.F. Robbins, J.R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17:4550-4557. http://dx.doi.org/10.1158/1078-0432.CCR-11.-0116
45. Saric, T., S.-C. Chang, A. Hattori, I.A. York, S. Markant, K.L. Rock, M. Tsujimoto, and A.L. Goldberg. 2002. An IFN-gamma-induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 3:1169-1176. http://dx.doi.org/10.1038/ni859
46. Schietinger, A., A. Arina, R.B. Liu, S. Wells, J. Huang, B. Engels, V. Bindokas, T. Bartkowiak, D. Lee, A. Herrmann, et al. 2013. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. OncoImmunology. 2:e26677. http://dx.doi.org/10.4161/onci.26677
47. Serwold, T., F. Gonzalez, J. Kim, R. Jacob, and N. Shastri. 2002. ERA AP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature. 419:480-483. http://dx.doi.org/10.1038/nature01074
48. Sidney, J., S. Southwood, C. Oseroff, M.F. del Guercio, A. Sette, and H.M. Grey. 2001. Measurement of MHC/peptide interactions by gel filtration. Curr. Protoc. Immunol. Chapter 18:3
49. Sidney, J., E. Assarsson, C. Moore, S. Ngo, C. Pinilla, A. Sette, and B. Peters. 2008. Quantitative peptide binding motifs for 19 human and mouse MHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4:2. http://dx.doi.org/10.1186/1745.-7580-4-2
50. Spiotto, M.T., D.A. Rowley, and H. Schreiber. 2004. Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10:294-298. http://dx.doi.org/10.1038/nm999
51. + T cell effector function in SV40 T antigen transgenic mice. J. Immunol. 171:697-707. http://dx.doi.org/10.4049/jimmunol.171.2.697
52. Suh, W.K., M.F. Cohen-Doyle, K. Fruh, K. Wang, P.A. Peterson, and D.B. Williams. 1994. Interaction of MHC class I molecules with the transporter associated with antigen processing. Science. 264:1322-1326. http://dx.doi.org/10.1126/science.8191286
53. Theobald, M., J. Biggs, D. Dittmer, A.J. Levine, and L.A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA. 92:11993-11997. http://dx.doi.org/10.1073/pnas.92.26.11993
54. Theobald, M., T. Ruppert, U. Kuckelkorn, J. Hernandez, A. Häussler, E.A. Ferreira, U. Liewer, J. Biggs, A.J. Levine, C. Huber, et al. 1998. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med. 188:1017-1028. http://dx.doi.org/10.1084./jem.188.6.1017
55. Ungureanu, D., P. Saharinen, I. Junttila, D.J. Hilton, and O. Silvennoinen. 2002. Regulation of Jak2 through the ubiquitin-proteasome pathway involves phosphorylation of Jak2 on Y1007 and interaction with SOCS-1. Mol. Cell. Biol. 22:3316-3326. http://dx.doi.org/10.1128/MCB.22.10.3316-3326.2002
56. van Hall, T., E.Z. Wolpert, P. van Veelen, S. Laban, M. van der Veer, M. Roseboom, S. Bres, P. Grufman, A. de Ru, H. Meiring, et al. 2006. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 12:417-424. http://dx.doi.org/10.1038/nm1381
57. Weimershaus, M., I. Evnouchidou, L. Saveanu, and P. van Endert. 2013. Peptidases trimming MHC class I ligands. Curr. Opin. Immunol. 25:90-96. http://dx.doi.org/10.1016/j.coi.2012.10.001
58. Willimsky, G., and T. Blankenstein. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 437:141-146. http://dx.doi.org/10.1038/nature03954
59. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA. 99:16168-16173. http://dx.doi.org/10.1073./pnas.242600099
60. York, I.A., M.A. Brehm, S. Zendzian, C.F. Towne, and K.L. Rock. 2006. Endoplasmic reticulum aminopeptidase 1 (ERAP1) trims MHC class I-presented peptides in vivo and plays an important role in immunodominance. Proc. Natl. Acad. Sci. USA. 103:9202-9207. http://dx.doi.org/10.1073/pnas.0603095103
61. Yu, P., D.A. Rowley, Y.-X. Fu, and H. Schreiber. 2006. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. 18:226-231. http://dx.doi.org/10.1016/j.coi.2006.01.004
62. Zhang, B., T. Karrison, D.A. Rowley, and H. Schreiber. 2008. IFN-gammaand TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J. Clin. Invest. 118:1398-1404. http://dx.doi.org/10.1172/JCI33522